Text Size Normal Text Sizing Button Medium Text Sizing Button Large Text Sizing Button Text Contrast Normal Contrast Button Reverse Contrast Button Switch to Spanish Language Press Room Contact Us Sitemap Sign In Register
Link to Homepage About AHAF
Donate Now Get Involved  
Alzheimer's Disease Research Macular Degeneration Research National Glaucoma Research


Sign up for Email Notifications
If you would like to be notified when submission deadlines are announced please click on the link below.

Sign up for new RFP announcements and submission deadline notifications.

This email list is not sold or distributed, and serves only as an annual reminder of the availability of research funding through the American Health Assistance Foundation (www.ahaf.org). Please follow instructions on the notification emails for removal requests.
 
Researchers:
Have you heard a story, statistic, or discovery that might interest the public? Let us know about it!
 
AHAF Research Grants Funding
Grant Funding for Alzheimer's Research
Grant Funding for Macular Degeneration Research
Grant Funding for Glaucoma Research
 

  

Alzheimer's Disease Research - Completed Award

Photo Pending

Jaehong Suh, Ph.D.

Massachusetts General Hospital
Charlestown, MA

Title: Effect of Novel Alzheimer’s diseaseAM10 Gene Mutations in Alzheimer's Disease
Non-Technical Title: Mutations in the Alzheimer’s diseaseAM10 gene can cause Alzheimer's disease

Mentor:
Rudolph Tanzi, Ph.D.
Massachusetts General Hospital

Duration: April 1, 2010 - March 31, 2012
Award Type: Research Fellowship
Award Amount: $100,000


Summary:

In this study, we are exploring the idea that newly discovered Alzheimer’s disease associated mutations in the Alzheimer’s diseaseAM10 gene attenuate the function of ADAM10. This is being accomplished by generating and characterizing genetically modified mice over-expressing either wild-type or mutant forms of ADAM10. We are also assessing the effects of these mutations on Alzheimer’s disease-like characteristics in a mouse model of the disease.

Details:

Alzheimer's disease is one of the leading causes of death and the most common form of dementia in the elderly. As the average life span is extended, the number of patients suffering from this disease is increasing dramatically, placing a huge burden on our healthcare system and on our global society. The incidence of Alzheimer’s disease increases with age and doubles every five years after age 60. Currently there exists no effective treatment to stop or slow the progression of this devastating disease. Although an enormous amount of effort and resources have been devoted to research and clinical trials aimed at finding effective therapeutic interventions, the cause of this disease remains unclear. In this study we are attempting to validate our genetic findings from Alzheimer’s disease families using a transgenic mouse model system. The novel mutations were found in the ADAM10 gene and can increase the production of neurotoxic peptide, called amyloid beta, which is considered a major factor for Alzheimer’s disease progression. The results from this study can provide critical in vivo evidence for the cause of late-onset Alzheimer’s disease. Moreover, the data emerging from this study would also serve as a firm foundation for the discovery and development of new drugs targeting ADAM10 for the treatment and prevention of Alzheimer’s disease.